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Abstract
Background:  In patients with chronic respiratory disease, Pneumocystis jirovecii (P. jirovecii)
colonization is observed, and may influence disease progression and systemic inflammation.
Pneumocystis pneumonia causes interstitial changes, so making a diagnosis of PCP in patients who
have interstitial pneumonia (IP) with P. jirovecii colonization is sometimes difficult based on
radiography.
Methods: This study investigated the prevalence of P. jirovecii colonization in IP patients and
assessed pulmonary injury due to P. jirovecii colonization by measurement of serum markers (KL-6,
SP-A, SP-D, and (1→3)  β-D-glucan (β-D-glucan)) and the peripheral lymphocyte counts,
prospectively. A total of 75 patients with idiopathic pulmonary fibrosis (n = 29), collagen vascular-
related interstitial pneumonia (n = 19), chronic bronchitis or pneumonia (n = 20), and Pneumocystis
pneumonia (n = 7) were enrolled in this prospective study. P. jirovecii DNA was detected in sputum
samples, while serum markers and the lymphocyte count were measured in the peripheral blood.
Results: IP patients (idiopathic pulmonary fibrosis and collagen vascular-related IP) who received
oral corticosteroids had a high prevalence of P. jirovecii colonization (23.3%). In IP patients, oral
corticosteroid therapy was a significant risk factor for P. jirovecii colonization (P < 0.05). Serum
markers did not show differences between IP patients with and without P. jirovecii colonization. The
β-D-glucan level and lymphocyte count differed between patients with Pneumocystis pneumonia or
P. jirovecii colonization.
Conclusion: Serum levels of KL-6, SP-A, SP-D, and β-D-glucan were not useful for detecting P.
jirovecii colonization in IP patients. However, the serum β-D-glucan level and lymphocyte count
were useful for distinguishing P. jirovecii colonization from pneumocystis pneumonia in IP patients.
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Backgrounds
Pneumocystis jirovecii (P. jirovecii) is a fungus, and a high
prevalence of P. jirovecii colonization has been reported
among non-human immunodeficiency virus (HIV)-
infected immunocompetent patients with primary respi-
ratory disease [1-3]. Interstitial pneumonia (IP) is also
associated with a high colonization rate of P. jirovecii [4].
The mortality rate of patients with acute exacerbation of IP
is 78% after hospital admission [5]. After acute exacerba-
tion of IP occurs in IP patient with P. jirovecii colonization,
it is difficult to distinguish IP associated with Pneumocystis
pneumonia (PCP) from IP without PCP based on the clin-
ical and radiological features. When P. jirovecii is detected
in sputum or bronchoalveolar lavage (BAL) fluid from IP
patients with exacerbation, the clinician has to determine
whether the patient has infection or colonization by P.
jirovecii, and whether treatment should include sulfameth-
oxazole/trimethoprim (ST). Serum levels of KL-6 [6], sur-
factant protein A (SP-A), and surfactant protein D (SP-D)
are used as markers of active IP [7]. KL-6 is an epithelial
mucin and also membrane glycoprotein classified as clus-
ter 9. KL-6 is more prominent in injured type II pneumo-
cytes, and leaked into blood flow [6,8]. SP-A and SP-D are
calcium-dependent lectins, and prominently produced by
type II pneumocytes and Clara cells in injured lung [9].
PCP infection leads the accumulation of neutrophils and
CD8 lymphocytes, and elicits the inflammatory mediator
of macrophage inflammatory protein (MIP)-2, inter-
leukin (IL)-8, and tumor necrosis factor (TNF)-α [10,11].
Mechansims of elevation of serum markers in PCP are
thought that these mediators induce type II pneumocytes
damages or hyperplasia, and this affects the elevations of
KL-6, SP-A and SP-D on serum levels. Although elevation
of serum levels of KL-6 and SP-A are reported in PCP,
while elevation of the serum (1→3) β-D-glucan (β-D-glu-
can) level has been reported as a marker of PCP [12,13],
whether these markers are affected by P. jirovecii coloniza-
tion has not yet been investigated in IP patients. In the
present study, we prospectively examined colonization by
P. jirovecii in IP patients, including those with idiopathic
pulmonary fibrosis (IPF) or collagen vascular disease-
related interstitial pneumonia (CVD), and also examined
P. jirovecii in patients with chronic bronchitis or pneumo-
nia (CB/Pneumonia). Furthermore, we compared the lev-
els of these serum markers between IP patients with or
without P. jirovecii colonization to determine whether the
markers were affected by colonization.
Methods
Subjects
A total of 75 patients were enrolled in this prospective
study. The IPF group (n = 29, men/women = 18/11, age =
64.7 ± 10.2 years) included 22 patients with usual intersti-
tial pneumonia (UIP) and 7 patients with non-specific
interstitial pneumonia (NSIP). The CVD group (n = 19,
men/women = 10/9, age = 63.6 ± 7.8 years) included 11
patients with rheumatoid arthritis, 3 with polymyositis, 2
with polyarteritis nodosa, 1 with dermatomyositis, 1 with
mixed connective tissue disease, and 1 with Sjögren syn-
drome. The CB/Pneumonia group (n = 20) included 10
men and 10 women aged 66.8 ± 9.5 years. The PCP group
(n = 7, men/women = 4/3, age = 61.6 ± 10.8 years)
included 1 patient with ulcerative colitis, 3 with lung can-
cer, 1 with adrenal deficiency, 1 with human immunode-
ficiency virus, and 1 with polymyositis. The numbers of
patients who received the oral corticosteroid therapy were
11 patients in UIP, 5 patients in NSIP, 14 patients in CVD
and 1 patient in PCP. The diagnosis of IPF was made by
using the American Thoracic Society/European Respira-
tory Society (ATS/ERS) International Multidisciplinary
Consensus Classification of Idiopathic Interstitial Pneu-
monias [14]. PCP was diagnosed from the detection of P.
jirovecii DNA in sputum or BAL by PCR, typical radio-
graphic features, typical symptoms [15], and the course of
chest symptoms and pulmonary changes on CT or chest
radiographs. A diagnosis of P. jirovecii colonization was
based on the detection of P. jirovecii DNA in induced spu-
tum by PCR, no changes of chest X-ray films or chest CT
scans for two months, no change of oxygen saturation for
two months, no past or current PCP infection or HIV
infection, no treatment with ST for PCP, and no clinical
signs of PCP [16]. Patients receiving oral corticosteroids at
doses above 5 mg/day were defined as the IP patients on
corticosteroid therapy. This study was conducted accord-
ing to the guidelines of the Declaration of Helsinki and
approved by institutional review board. All of the patients
are given written informed consent.
Laboratory tests
Induced sputum samples were collected after inhalation
of ultrasonically nebulized hypertonic saline. Sputum
samples were subjected to PCR according to the method
of Wakefield et al [17,18] using AmpliTaq DNA polymer-
ase (Roche Diagnostics, Switzerland) and a PJ-2000 ther-
mal cycler (Perkin Elmer, U.S.A). A peripheral blood
sample was collected, and the lymphocyte count, CD4 T
cell count, and serum KL-6 level were measured as
described previously [19]. SP-A and SP-D were measured
by using the SP-A test Kokusai F kit (Sysmex, Japan) and
SP-D Yamasa EIA kit (Yamasa, Japan), respectively [7,20].
β-D-glucan was measured by the β-D-glucan test (Wako,
Japan) based on a kinetic turbidmetric assay [21].
Statistics
Categorical data were compared by using the chi-squared
test or Fisher's exact test. The significance of differences
between groups was calculated by Dunnet's test after the
Kruskal-Wallis test. The relation of oral corticosteroid
therapy (odds ratio) to P. jirovecii colonization was calcu-
lated by using the chi-squared test for comparison
between IP patients receiving oral corticosteroids and
those not on corticosteroid therapy. The significance ofBMC Infectious Diseases 2009, 9:47 http://www.biomedcentral.com/1471-2334/9/47
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differences between IP patients on oral corticosteroid
therapy with P. jirovecii colonization and IP patients on
corticosteroid therapy without P. jirovecii colonization
was calculated by the Man-Whitney test. Statistical signif-
icance was defined as P <0.05.
Results
The rate of P. jirovecii colonization on pulmonary diseases
The P. jirovecii colonization rates were 13.8% in the IPF
group and 15.8% in CVD group, while it was 0% in the
CB/Pneumonia group. The P. jirovecii colonization rate of
IP patients on oral corticosteroid therapy (n = 30), i.e., IPF
and CVD patients on corticosteroids with P. jirovecii colo-
nization, was significantly higher (23.3%) than the rate
(0%) for IP patients (n = 18) who were not on corticoster-
oids (Fig. 1a). The odds ratio for P. jirovecii colonization
in IP patients receiving oral corticosteroids was 16.3 (P =
0.0097). The use of oral corticosteroids was high in
patients with IPF (55.2%) and CVD (73.7%), and the rate
was not significantly different between the IPF group and
the CVD group. None of the CB/pneumonia patients were
on oral corticosteroid therapy, and only one patient was
receiving oral corticosteroids in the PCP group (Fig. 1b).
Serum marker levels and lymphocytes count in pulmonary 
diseases
Serum levels of KL-6 were higher in the IPF (1278.5 ±
740.4) and PCP (1488 ± 1086.1) groups than in the CB/
Pneumonia group (375.8 ± 300.8). The KL-6 level of the
CVD group (898.2 ± 605.3) was not different from that of
the PCP group (Fig. 2a). SP-A levels did not show signifi-
cant differences among the IPF group (88.7 ± 36.2), CVD
group (73.2 ± 52.1), CB/Pneumonia group (73.3 ± 41.4),
and PCP group (121.9 ± 24.7) (Fig. 2b). SP-D levels also
did not show significant differences among the IPF group
(166.9 ± 111.1), CVD group (92.7 ± 67.7), CB/Pneumo-
nia group (131 ± 71.0), and PCP group (194.1 ± 157.5)
(Fig. 2c). The β-D-glucan level of the PCP (32.8 ± 35.1)
was significantly higher than that of the other groups (the
IPF, CVD, and CB/pneumonia groups all had levels under
the detection limit of <3.4) (Fig. 2d). Levels of serum
markers did not show any significant differences between
IP patients with and without P. jirovecii colonization on
oral corticosteroid therapy with respect to KL-6 (1370 ±
810.4 vs. 1030.6 ± 594.6), SP-A (86.6 ± 32.8 vs. 73.5 ±
44.5), SP-D (142.8 ± 145.1 vs. 102.3 ± 121.9), and β-D-
glucan (both groups were under the detection limit) (Figs.
2e, f, g and 2h). The lymphocyte count of the PCP group
(397.1 ± 151.6) was significantly lower than those of the
other groups (IPF: 1480.2 ± 917.1; CVD: 1543.8 ± 919.6;
and CB/pneumonia: 1118.4 ± 445.3). CD4 T cell counts
showed no statistical differences among the four groups
(IPF: 614.8 ± 469; CVD: 711.8 ± 431.1; CB/pneumonia:
403.3 ± 369.9; and PCP: 129 ± 96.7) (Figs. 3a, b). The
lymphocyte count and CD4 T cell count showed no statis-
tical differences between IP patients with and without P.
jirovecii colonization on oral corticosteroids (Figs. 3c, d).
The peripheral lymphocyte count of the former group was
1206.7 ± 859.7 and that of the latter group was 1144.6 ±
560.0, while the CD4 T cell count was 651.6 ± 565.6 and
401.5 ± 235.4, respectively.
Discussion
P. jirovecii colonization occurs in patients with chronic
respiratory disease, even in the absence of HIV infection
[22]. The P. jirovecii colonization rate is 15.5% in pregnant
women [23] and 10% to 40% in chronic obstructive dis-
ease (COPD) patients [1,24,25]. In the present study, IP
patients who received oral corticosteroid therapy had a
high P. jirovecii colonization rate of 23.3%. Oral steroid
therapy was a statistical risk factor for P. jirovecii coloniza-
tion. Furthermore, the serum β-D-glucan level and the
lymphocyte count were useful to distinguish IP with P.
jirovecii colonization patients from PCP patients, while
serum SP-A, SP-D, and KL-6 levels were not useful. These
serum markers were not affected by P. jirovecii coloniza-
tion.
β-D-glucan is a major component of the P. jirovecii cyst
wall [26]. Infection is established by adhesion of the
trophic form of Pneumocystis to the alveolar epithelium,
where it proliferates [27]. One of the reasons for the dif-
ferent levels of β-D-glucan in PCP and P. jirovecii coloni-
zation was considered to be Pneumocystis  proliferation.
Cyst wall β-D-glucan is partly responsible for the inflam-
matory response in the lung [28,29]. SP-A and SP-D levels
P. Jirovecii colonization rate in the including idiopathic pulmo- nary fibrosis (IPF), collagen vascular-related IP (CVD), and  chronic bronchitis (CB)/pneumonia (pneumo) groups Figure 1
P. Jirovecii colonization rate in the including idio-
pathic pulmonary fibrosis (IPF), collagen vascular-
related IP (CVD), and chronic bronchitis (CB)/pneu-
monia (pneumo) groups. Patients with IP (IPF and CVD) 
were divided into groups receiving oral corticosteroid ther-
apy and without corticosteroid therapy (a). The rates of oral 
corticosteroids use in IPF, CVD, CB/pneumonia and Pneumo-
cystis pneumonia (PCP) group (b).BMC Infectious Diseases 2009, 9:47 http://www.biomedcentral.com/1471-2334/9/47
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were reported to be affected by PCP infection via inflam-
matory mediators [10,11] or reported to influence on PCP
infection, and to play a role in host defenses against P.
jirovecii  [30-32]. Based on these reports, we examined
serum KL-6, SP-A, and SP-D levels in IP patients with or
without P. jirovecii colonization on oral corticosteroids.
Our results indicated that these markers did not show any
difference between IP patients with and without P. jirovecii
colonization, suggesting that KL-6, SP-A, and SP-D levels
were not affected by P. jirovecii colonization in IP patients.
Although there has been a report that P. jirovecii coloniza-
tion plays a role in systemic inflammation in COPD
patients [33], we did not examine the effect of P. jirovecii
on other cytokines or on disease progression. To deter-
mine the effect of P. jirovecii colonization on serum mark-
ers, it would be necessary to compare the changes of each
marker when new P. jirovecii colonization occurs in a
patient. Since present study did not show the affect of P.
jirovecii colonization on serum markers of KL-6, SP-A and
SP-D, we could not determine the value of prophylaxis
with ST for IP patients with P. jirovecii colonization against
pulmonary injury. There are unsolved problems regarding
droplet transmission of P. jirovecii and the existence of
drug-resistant organisms associated with prophylaxis of
ST. Further analysis will be needed to determine the effi-
cacy of ST prophylaxis for IP patients with P. jirovecii col-
onization on oral corticosteroid therapy.
Recently, quantification of P. jirovecii DNA by real-time
PCR targeting the heat shock protein 70 gene was reported
to be useful for discrimination between colonization and
infection with this organism [34]. When P. jirovecii is
Serum markers levels in pulmonary diseases Figure 2
Serum markers levels in pulmonary diseases. Serum levels of KL-6, SP-A, SP-D, and β-D glucan in patients with respira-
tory diseases of idiopathic pulmonary fibrosis (IPF), collagen vascular-related IP (CVD), chronic bronchitis (CB)/pneumonia 
(pneumo) and pneumocystis pneumonia (PCP) groups. Levels of KL-6, SP-A, SP-D, and β-D glucan in IP patients on oral corti-
costeroids with P. jirovecii colonization (steroid (+)) colniz (+)) versus patients without P. jirovecii colonization (steroid (+)) col-
niz (-)).BMC Infectious Diseases 2009, 9:47 http://www.biomedcentral.com/1471-2334/9/47
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detected in sputum or bronchoalveolar lavage (BAL) fluid
from a patient with exacerbation of IP, the clinician has to
determine whether a patient has infection or coloniza-
tion. To make a diagnosis of PCP, real-time PCR of the
HSP 70 gene might be used in the clinical setting.
Conclusion
In conclusion, serum markers (KL-6, SP-A, and SP-D)
were not higher in IP patients with P. jirovecii colonization
than in those without colonization. IP patients receiving
oral corticosteroid therapy had a high prevalence of P.
jirovecii colonization, and oral corticosteroids are a risk
factor for colonization. When patients develop exacerba-
tion of IP, to diagnosis PCP or P. jirovecii colonization, it
seems to be useful to know in advance whether the patient
is a carrier of P. jirovecii, and to also examine the serum β-
D-glucan level and the peripheral lymphocyte count.
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